Home > Neurology > MTIS 2020 > Contents > No new cardiovascular safety concerns with long-term use of lasmiditan

No new cardiovascular safety concerns with long-term use of lasmiditan

Presented By
Dr H. Hochstetler

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
MTIS 2020
Trial
Phase 3, GLADIATOR
  Lasmiditan is a selective 5-HT1F receptor agonist that lacks the vasoconstrictive activity associated with other acute treatments for migraine. In an interim analysis of the long-term GLADIATOR trial, no vasoconstriction-related cardiovascular events occurred during the lasmiditan treatment-emergent period [1]. Previous studies showed that lasmiditan is associated with a low risk of cardiovascular treatment-emergent adverse events (AEs), specifically palpitations and tachycardia. No difference in cardiovascular treatment-emergent AE frequency in subjects with or without cardiovascular risk factors was found. Patients who previously participated in phase 3, placebo-controlled, single-attack lasmiditan studies could be enrolled in the open-label, randomised GLADIATOR trial. These included patie...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on